INTELLIA THERAPEUTICS INC. - COMMON STOCK

12,25

20-февраля-25 16:45:00

15 мин. задержка

Акции

-0,03

-0,24%

Сегодняшний диапазон

12,03 - 12,84

ISIN

N/A

Источник

NASDAQ

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

18 ноя 2024 10:10:43 Источник NetDania Notify
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

16 ноя 2024 10:16:00 Источник Nasdaq GlobeNewswire
Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

07 ноя 2024 07:30:00 Источник Nasdaq GlobeNewswire
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

05 ноя 2024 16:01:00 Источник Nasdaq GlobeNewswire
NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

31 окт 2024 09:45:01 Источник NetDania Notify
Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024

31 окт 2024 07:30:00 Источник Nasdaq GlobeNewswire
NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

30 окт 2024 09:45:22 Источник NetDania Notify
NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

29 окт 2024 11:48:28 Источник NetDania Notify
NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

24 окт 2024 09:46:04 Источник NetDania Notify
Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

24 окт 2024 08:01:00 Источник Nasdaq GlobeNewswire
NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

10 окт 2024 09:45:05 Источник NetDania Notify
Intellia Therapeutics Announces New Date for Upcoming Investor Webcast

10 окт 2024 07:30:00 Источник Nasdaq GlobeNewswire
Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

07 окт 2024 07:30:00 Источник Nasdaq GlobeNewswire
NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

04 окт 2024 10:23:57 Источник NetDania Notify
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 окт 2024 16:01:00 Источник Nasdaq GlobeNewswire
NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

03 окт 2024 09:45:08 Источник NetDania Notify
NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

02 окт 2024 09:45:32 Источник NetDania Notify
NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

01 окт 2024 13:25:49 Источник NetDania Notify
Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions

01 окт 2024 07:30:00 Источник Nasdaq GlobeNewswire
Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting

12 сен 2024 07:30:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.